Study Reports Longest Median Survival Rate for Stage 4 Lung Cancer

Advancements in cancer therapy have improved survival time for patients with non-small cell lung cancer (NSCLC), according to a new study published in the Journal of Thoracic Oncology.
 
From 1995 to 2001, patients with NSCLC, an aggressive form of lung cancer, had a 15% chance of being alive 5 years later, according to the National Cancer Institute. New data suggest that the percentage of patients alive 5 years after diagnosis has jumped significantly, likely due to the advancement of targeted treatments for the disease.
 
For the study, the researchers examined 110 patients diagnosed with stage 4 NSCLC whose tumors tested positive for rearrangements of the anaplastic lymphoma kinase (ALK) gene between 2009 and 2017. Of the patients in the study, 83% were never smokers and had a median age of 53 years. Most of the patients received crizotinib as their initial ALK inhibitor, according to the study. After treatment with crizotinib, 78% of patients who showed evidence of worsening disease were transitioned to another ALK inhibitor.
 
With a median follow-up of 47 months, the median overall survival (OS) from diagnosis of stage 4 disease was 6.8 years, indicating that 50% of patients were alive 6.8 years after diagnosis versus only 2% being alive after 5 years.
 
“Many studies have reported shorter overall survival for patients with stage IV ALK+ NSCLC treated with crizotinib,” study author Jose Pacheco, MD, investigator at CU Cancer Center, said in a press release. “These studies had lower survival outcomes in large part because of a lower percentage of patients receiving next-gen ALK inhibitors after progressing on crizotinib. Patients here were getting next-gen ALK inhibitors in phase 1 and 2 clinical trials before many other centers had access to them.”
 
Additionally, the researchers found that brain metastasis at diagnosis of stage 4 disease and year of stage 4 disease presentation did not influence OS, but more organs with tumor at diagnosis was associated with worse OS.
 
Dr Pacheco noted that the use of pemetrexed-based chemotherapies influenced survival, as the therapy works especially well against the ALK+ form of the disease.
 
“We try to use mainly pemetrexed-based chemotherapies in ALK+ lung cancer,” he said in the release. “It is possible shorter survival in other studies may be associated with use of non-pemetrexed based chemotherapies.”
 
“At this point, 6.8 years is one of the longest median survivals ever reported for a NSCLC subpopulation stage IV disease,” Pacheco concluded. “It shows the benefit of targeted therapy and how it’s changing survival for a lot of patients. And I think it suggests that for some types of NSCLC, it may become much more of a chronic condition rather than a terminal disease.”
 
References
  1. Pacheco JM, Gao D, Smith D, et al. Natural history and factors associated with overall survival in stage IV ALK rearranged non-small cell lung cancer. Journal of Thoracic Oncology. 2018. https://doi.org/10.1016/j.jtho.2018.12.014
  2. With the right care, patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis [news release]. University of Colorado Cancer Center’s website. https://coloradocancerblogs.org/with-the-right-care-patients-now-living-a-median-6-8-years-after-stage-iv-alk-lung-cancer-diagnosis/. Accessed January 2, 2019.
 
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.
Colon cancer may spread to other parts of the body before original tumors are clinically detectable.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$